Abstract
Despite the clinical success of immunotherapy in certain cancers, patient sensitivity and resistance remain persistent challenges. As the primary energy powerhouses of eukaryotic cells, mitochondria exhibit dysfunction and metabolic perturbations that alter endogenous molecular expression (1,2). Mitochondria also extensively participate in emerging cell death processes such as ferroptosis and cuproptosis, consequently reshaping the infiltration and functional state of tumor immune cells. Exploring mitochondria-associated targets and their crosstalk with cell death pathways represents a potential approach to overcome immunotherapy resistance.

This publication has 8 references indexed in Scilit: